La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), a clinical-stage investigational product to treat conditions characterized by iron overload, including hereditary hemochromatosis, beta thalassemia, sickle cell disease, myelodysplastic syndrome, and polycythemia vera.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone858-207-4264
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10.06 million
Profitability
Miscellaneous
Employees169
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
La Jolla Pharmaceutical (NASDAQ:LJPC) Frequently Asked Questions
What is La Jolla Pharmaceutical's stock symbol?
La Jolla Pharmaceutical trades on the NASDAQ under the ticker symbol "LJPC."
How were La Jolla Pharmaceutical's earnings last quarter?
La Jolla Pharmaceutical (NASDAQ:LJPC) posted its quarterly earnings data on Monday, May, 6th. The biopharmaceutical company reported ($1.17) EPS for the quarter, beating analysts' consensus estimates of ($1.31) by $0.14. The biopharmaceutical company earned $4.40 million during the quarter, compared to analysts' expectations of $4.98 million. La Jolla Pharmaceutical had a negative return on equity of 337.55% and a negative net margin of 1,324.04%. View La Jolla Pharmaceutical's Earnings History.
When is La Jolla Pharmaceutical's next earnings date?
What price target have analysts set for LJPC?
5 brokerages have issued twelve-month price objectives for La Jolla Pharmaceutical's shares. Their predictions range from $6.00 to $27.00. On average, they anticipate La Jolla Pharmaceutical's share price to reach $15.50 in the next twelve months. This suggests a possible upside of 59.0% from the stock's current price. View Analyst Price Targets for La Jolla Pharmaceutical.
What is the consensus analysts' recommendation for La Jolla Pharmaceutical?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for La Jolla Pharmaceutical in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for La Jolla Pharmaceutical.
What are Wall Street analysts saying about La Jolla Pharmaceutical stock?
Here are some recent quotes from research analysts about La Jolla Pharmaceutical stock:
- 1. According to Zacks Investment Research, "LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory diseases. " (5/14/2019)
- 2. HC Wainwright analysts commented, "We base our $26 price target on a sum-of-the-parts analysis based on: (1) the P/E value of La Jolla’s current commercial business (Giapreza); (2) an NPV of its pipeline (LJPC-401); and (3) our estimated year-end 2019 fully diluted net cash of $1.69/share to arrive at our price target. We value the current commercial business at $8.76 per share and the pipeline at $15.68 per share. The commercial business value is based on a P/E multiple assumption of 30x our 2024E EPS of $0.51, discounted at 15%." (4/24/2019)
Has La Jolla Pharmaceutical been receiving favorable news coverage?
Press coverage about LJPC stock has been trending somewhat positive recently, InfoTrie reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. La Jolla Pharmaceutical earned a news sentiment score of 1.3 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for La Jolla Pharmaceutical.
Who are some of La Jolla Pharmaceutical's key competitors?
Some companies that are related to La Jolla Pharmaceutical include Cortexyme (CRTX), Atara Biotherapeutics (ATRA), NanoString Technologies (NSTG), Voyager Therapeutics (VYGR), Nightstar Therapeutics (NITE), Twist Bioscience (TWST), GENFIT S A/ADR (GNFT), Adverum Biotechnologies (ADVM), Vericel (VCEL), BAVARIAN NORDIC/S (BVNRY), MeiraGTx (MGTX), Osiris Therapeutics (OSIR), Autolus Therapeutics (AUTL), Precision BioSciences (DTIL) and Heska (HSKA).
What other stocks do shareholders of La Jolla Pharmaceutical own?
Who are La Jolla Pharmaceutical's key executives?
La Jolla Pharmaceutical's management team includes the folowing people:
- Dr. George F. Tidmarsh, Pres, CEO, Sec. & Director (Age 59)
- Mr. Dennis M. Mulroy, Chief Financial Officer (Age 64)
- Ms. Jennifer A. Carver, Chief Operating Officer (Age 65)
- Mr. James M. Rolke, Chief Scientific Officer (Age 50)
- Dr. Lakhmir S. Chawla, Chief Medical Officer (Age 48)
Who are La Jolla Pharmaceutical's major shareholders?
La Jolla Pharmaceutical's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (14.99%), Fosun International Ltd (1.54%), Spark Investment Management LLC (1.42%), Marshall Wace North America L.P. (1.38%), Marshall Wace LLP (0.53%) and First Midwest Bank Trust Division (0.25%). Company insiders that own La Jolla Pharmaceutical stock include George F Tidmarsh, James Rolke, Jennifer Carver, Kevin C Tang, Lakhmir S Chawla, Laura L Douglass, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Institutional Ownership Trends for La Jolla Pharmaceutical.
Which institutional investors are buying La Jolla Pharmaceutical stock?
LJPC stock was purchased by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Spark Investment Management LLC, FMR LLC, Fosun International Ltd, Marshall Wace LLP, First Midwest Bank Trust Division, Trellus Management Company LLC and Virtu Financial LLC. Company insiders that have bought La Jolla Pharmaceutical stock in the last two years include George F Tidmarsh, James Rolke, Jennifer Carver, Kevin C Tang, Lakhmir S Chawla, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for La Jolla Pharmaceutical.
How do I buy shares of La Jolla Pharmaceutical?
Shares of LJPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is La Jolla Pharmaceutical's stock price today?
One share of LJPC stock can currently be purchased for approximately $9.75.
How big of a company is La Jolla Pharmaceutical?
La Jolla Pharmaceutical has a market capitalization of $264.23 million and generates $10.06 million in revenue each year. The biopharmaceutical company earns $-199,470,000.00 in net income (profit) each year or ($7.85) on an earnings per share basis. La Jolla Pharmaceutical employs 169 workers across the globe.View Additional Information About La Jolla Pharmaceutical.
What is La Jolla Pharmaceutical's official website?
How can I contact La Jolla Pharmaceutical?
La Jolla Pharmaceutical's mailing address is 4550 TOWNE CENTRE COURT, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-207-4264 or via email at [email protected]
MarketBeat Community Rating for La Jolla Pharmaceutical (NASDAQ LJPC)
MarketBeat's community ratings are surveys of what our community members think about La Jolla Pharmaceutical and other stocks. Vote "Outperform" if you believe LJPC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LJPC will underperform the S&P 500 over the long term. You may vote once every thirty days.
